Mesenchymal stromal cells from JAK2 V617F myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo.

Hemasphere · 2025 · PMC12374162 · PMID 40862221

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

did not reach statistical significanceno p-value reported

The JAK2 V617F VAF was generally maintained across both HD and ET MSC‐pre‐seeded scaffolds, with a slight trend towards a higher JAK2 V617F mutation burden in the ET MSC‐pre‐seeded scaffolds, though this result did not reach statistical significance (Figure 3E ).

also in 2,443 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Mesenchymal stromal cells from &lt;i&gt;JAK2&lt;/i&gt; &lt;sup&gt;&lt;i&gt;V617F&lt;/i&gt;&lt;/sup&gt; myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo.

The sentences

Mesenchymal stromal cells from <i>JAK2</i> <sup><i>V617F</i></sup> myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo.